SEC Company Response from PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Sep 28, 2010
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: Sept. 28, 2010 · CIK: 0001157075 · Accession: 0001262463-10-000110
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-68008
Referenced dates: September 20, 2010
Letter
September __, 2010
September 29, 2010
Vanessa Robertson/Staff Accountant
United States
Securities and Exchange Commission
100 F. Street, N.W.
Mail Stop 4561
Washington, D.C. 20549-3561
RE:
Nuvilex, Inc.
Your Letter of September 20, 2010
Item 4.02 Form 8-K
Filed September 15, 2010
File No. 333-68008
Ms. Robertson:
On September 28, 2010, Tim Matula, a member of the board of directors of Nuvilex, Inc., contacted you acknowledging receipt of the SEC letter dated September 20, 2010. Please let this letter serve as written confirmation that the Director requested an extension in responding to the letter, which was granted to October 19, 2010 by you.
Registrant wishes to acknowledge the following:
·
The Company is responsible for the adequacy and accuracy of the disclosures in the filing.
·
Staff comments, or changes to disclosures in response to staff comments in filings disclosed to the Staff, do not foreclose the Commission from taking any action with respect to the filing.
·
The Company may not assert the Staff comments as a defense in any proceeding initiated by the Commission or by any person under the Federal Securities Laws.
Respectfully submitted,
/s/ Patricia Gruden
Show Raw Text
CORRESP 1 filename1.htm September __, 2010 September 29, 2010 Vanessa Robertson/Staff Accountant United States Securities and Exchange Commission 100 F. Street, N.W. Mail Stop 4561 Washington, D.C. 20549-3561 RE: Nuvilex, Inc. Your Letter of September 20, 2010 Item 4.02 Form 8-K Filed September 15, 2010 File No. 333-68008 Ms. Robertson: On September 28, 2010, Tim Matula, a member of the board of directors of Nuvilex, Inc., contacted you acknowledging receipt of the SEC letter dated September 20, 2010. Please let this letter serve as written confirmation that the Director requested an extension in responding to the letter, which was granted to October 19, 2010 by you. Registrant wishes to acknowledge the following: · The Company is responsible for the adequacy and accuracy of the disclosures in the filing. · Staff comments, or changes to disclosures in response to staff comments in filings disclosed to the Staff, do not foreclose the Commission from taking any action with respect to the filing. · The Company may not assert the Staff comments as a defense in any proceeding initiated by the Commission or by any person under the Federal Securities Laws. Respectfully submitted, /s/ Patricia Gruden Patricia Gruden Interim President